title: Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.
abstract: Systems biology has proven to be a powerful tool to identify reliable predictors of treatment response in chronic hepatitis C virus (HCV) infection. In the present study, we studied patients with chronic HCV infection who responded to interferon (IFN)-based therapy, as evidenced by an absence of HCV RNA at the end of treatment, and focused on two issues that have not received much attention. First, we evaluated whether specific genes or gene expression patterns in blood were able to distinguish responder patients with a viral relapse from responder patients who remained virus negative after cessation of treatment. We found that patients with chronic HCV infection who were sustained responders and relapsers after IFN-based therapy showed comparable baseline clinical parameters and immune compositions in blood. However, at baseline, the gene expression profiles of a set of 18 genes predicted treatment outcome with an accuracy of 94%. Second, we examined whether patients with successful therapy-induced clearance of HCV still exhibited gene expression patterns characteristic of HCV or whether normalization of their transcriptome was observed. We observed that the relatively high expression levels of IFN-stimulated genes (ISGs) in patients with chronic HCV infection prior to therapy were reduced after successful IFN-based antiviral therapy (at 24 weeks of follow-up). These ISGs included the CXCL10, OAS1, IFI6, DDX60, TRIM5, and STAT1 genes. In addition, 1,428 differentially expressed non-ISGs were identified in paired pre- and posttreatment samples from sustained responders, which included genes involved in transforming growth factor beta (TGF-β) signaling, apoptosis, autophagy, and nucleic acid and protein metabolism. Interestingly, 1,424 genes with altered expression levels in responder patients after viral eradication were identified, in comparison to normal expression levels in healthy individuals. Additionally, aberrant expression levels of a subset of these genes, including the interleukin-32 (IL-32), IL-16, CCND3, and RASSF1 genes, were also observed at baseline. Our findings indicate that successful antiviral therapy for patients with chronic HCV infection does not lead to normalization of their blood transcriptional signature. The altered transcriptional activity may reflect HCV-induced liver damage in previously infected individuals.
  
  
  OBJECTIVE
  Tools to predict the efficacy of antiviral therapy for patients with HCV infection are important to select the optimal therapeutic strategy. Using a systems biology approach, we identify a set of 18 genes expressed in blood that predicts the recurrence of HCV RNA after cessation of therapy consisting of peginterferon and ribavirin. This set of genes may be applicable as a useful biomarker in clinical decision-making, since the number of genes included in the predictor is small and the correct prediction rate is high (94%). In addition, we observed that the blood transcriptional profile in patients with chronic HCV infection who were successfully treated is not normalized to the status observed in healthy individuals. Even 6 months after therapy-induced elimination of HCV RNA, gene expression profiles in blood are still altered in these patients with chronic HCV infection, strongly suggesting long-term modulation of immune parameters in previously infected patients.
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Jun
authors.initials: J
authors.lastname: Hou
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Gertine
authors.initials: G
authors.lastname: van Oord
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Zwier M A
authors.initials: ZM
authors.lastname: Groothuismink
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands Department of Internal Medicine, Infectious Diseases Section, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Mark A A
authors.initials: MA
authors.lastname: Claassen
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Kim
authors.initials: K
authors.lastname: Kreefft
authors.affiliation: Viroscience Lab, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Fatiha
authors.initials: F
authors.lastname: Zaaraoui-Boutahar
authors.affiliation: Center for Biomics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Wilfred F J
authors.initials: WF
authors.lastname: van IJcken
authors.affiliation: Viroscience Lab, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Albert D M E
authors.initials: AD
authors.lastname: Osterhaus
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands Liver Clinic University Health Network, Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Harry L A
authors.initials: HL
authors.lastname: Janssen
authors.affiliation: Viroscience Lab, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Arno C
authors.initials: AC
authors.lastname: Andeweg
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: de Knegt
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands p.a.boonstra@erasmusmc.nl.
authors.forename: Andre
authors.initials: A
authors.lastname: Boonstra
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D020869:Gene Expression Profiling; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology*; D054884:Host-Pathogen Interactions; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha
references.citation: N Engl J Med. 2001 Jul 5;345(1):41-52
references.pmid: 11439948
references.citation: J Interferon Cytokine Res. 2013 Jan;33(1):15-23
references.pmid: 23067362
references.citation: Hepatology. 2012 Sep;56(3):994-1003
references.pmid: 22407776
references.citation: PLoS One. 2011 Feb 24;6(2):e17232
references.pmid: 21390311
references.citation: Biochem Biophys Res Commun. 2013 Aug 23;438(2):324-8
references.pmid: 23891693
references.citation: J Gen Virol. 2010 Feb;91(Pt 2):382-8
references.pmid: 19846672
references.citation: PLoS One. 2011;6(5):e19799
references.pmid: 21603632
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
references.pmid: 11309499
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S35-46
references.pmid: 12407575
references.citation: Hepatology. 2007 Nov;46(5):1548-63
references.pmid: 17929300
references.citation: J Gastroenterol. 2013 Jan;48(1):132-43
references.pmid: 22766745
references.citation: Gastroenterology. 2010 Aug;139(2):499-509
references.pmid: 20434452
references.citation: Hepatology. 2011 Jun;53(6):1819-29
references.pmid: 21381070
references.citation: Gastroenterology. 2005 May;128(5):1437-44
references.pmid: 15887125
references.citation: J Hepatol. 2008 Oct;49(4):634-51
references.pmid: 18715665
references.citation: J Viral Hepat. 2012 Feb;19(2):e97-104
references.pmid: 22239532
references.citation: J Med Virol. 2013 Mar;85(3):441-8
references.pmid: 23280583
references.citation: Oncogene. 2001 Mar 22;20(12):1509-18
references.pmid: 11313894
references.citation: Nat Med. 2013 Jul;19(7):850-8
references.pmid: 23836235
references.citation: N Engl J Med. 2013 May 16;368(20):1931-2
references.pmid: 23607592
references.citation: Biostatistics. 2005 Jan;6(1):111-7
references.pmid: 15618531
references.citation: Proc Natl Acad Sci U S A. 2008 May 13;105(19):7034-9
references.pmid: 18467494
references.citation: J Virol. 2007 Apr;81(7):3391-401
references.pmid: 17267482
references.citation: J Hepatol. 2012 Nov;57(5):1110-25
references.pmid: 22659520
references.citation: Gut. 2009 Jun;58(6):846-58
references.pmid: 19074178
references.citation: N Engl J Med. 2009 Aug 6;361(6):580-93
references.pmid: 19625712
references.citation: Immunity. 2008 Jul 18;29(1):150-64
references.pmid: 18631455
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
references.pmid: 12883005
references.citation: Clin Infect Dis. 2009 Nov 1;49(9):1397-401
references.pmid: 19814621
references.citation: PLoS One. 2012;7(11):e49389
references.pmid: 23145169
references.citation: J Virol. 2011 Jun;85(11):5323-30
references.pmid: 21450832